Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05981573
Other study ID # 1358643
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 2024
Est. completion date September 2024

Study information

Verified date February 2024
Source Cari Health Inc.
Contact Foster P Carr, MD
Phone 6192343725
Email drcarr@carihealth.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Proof of concept: Pilot Study A Pilot, proof of concept, observational study with a long-term goal to develop a minimally invasive wearable Remote Medication Monitor (RMM) that provides continuous, real-time data on methadone levels in interstitial fluid (ISF). An RMM could be used as a medication adherence monitor and would allow for the physician, counselor, patient, or family member to remotely verify that a physician-prescribed dose has been taken.


Description:

The investigator will conduct a non-randomized, non-blinded, feasibility study at a single center in the United States. The study will include up to 20 subjects of an equal number of male and female adults (ages 18-70) who have a prescription for methadone for chronic pain. In Aim 1, the investigator will determine if an RMM can assess the status of taking a prescribed dose of methadone, using biosamples (i.e., ISF, blood) collected from subjects and tested in a laboratory setup. Biosample collections and pharmacokinetic monitoring will take up to 6 consecutive hours. By completing this aim, the investigator will determine if a physician is able to recognize the peak and trough of a methadone dose using ex vivo Differential Pulse Voltammetry (DPV). In Aim 2, the investigator will determine if an RMM can continuously assess the status of taking a prescribed dose of methadone over time, by inserting the intradermal microneedle sensing elements into the subjects' skin. The electronics for the RMM prototypes will consist of commercially available benchtop potentiostats like the PalmSens Sensit BT (https://www.palmsens.com/product/palmsens4/) or CH Instruments 660D (https://www.chinstruments.com/) and will not be in direct contact with the skin. Biosample collections (i.e., ISF, blood) and pharmacokinetic monitoring will occur over a 6-hour period. By completing this aim, the investigator will determine if a physician is able to recognize the pharmacokinetic profile of a taken dose of methadone. The physician will see a dosing curve display generated from intradermal microneedle sensing elements that are worn continuously on the skin. Completion of Aims 1-2 will require two separate visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date September 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age 18-70 - A prescription for methadone for chronic pain at a dose of 10mg or more for at least one week. - Taking methadone as prescribed during the last 4 days before consent to participate in the study. Exclusion Criteria: - Age <18 or >70 - A condition preventing or complicating ISF collection - dermatological (skin) condition - immunodeficiency - recent blood donation - anemia - end stage renal disease - liver cirrhosis - cancer - congestive heart failure - bleeding diathesis - tuberculosis (TB) - Any active severe depression - suicidal ideation - mania symptoms - Pregnancy - Intending to become pregnant during the course of the study - Enrolled in a substance use disorder treatment program - Under a conservatorship.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ISF extraction device 1
FDA approved microneedle attached to blotter paper tested for ability to extract 1ul of interstitial fluid
Diagnostic Test:
Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo
Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Electrochemical Assay
Device:
Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo
Measurement of Methadone and its metabolites in ISF with LC-MS and DPV
Drug:
Measurement of Methadone in ISF before and after taking prescribed dose
Measurement of methadone in ISF using DPV ex vivo versus in vivo . (Accuracy comparison - sensitivity, specificity, level of detection, and standard deviations )
Device:
ISF Extraction Device 2
2 hour periods of continuous ISF collection for analysis

Locations

Country Name City State
United States Synergy Lemon Grove California

Sponsors (1)

Lead Sponsor Collaborator
Cari Health Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Friedel M, Werbovetz B, Drexelius A, Watkins Z, Bali A, Plaxco KW, Heikenfeld J. Continuous molecular monitoring of human dermal interstitial fluid with microneedle-enabled electrochemical aptamer sensors. Lab Chip. 2023 Jul 12;23(14):3289-3299. doi: 10.1039/d3lc00210a. — View Citation

Gomes NO, Raymundo-Pereira PA. On-Site Therapeutic Drug Monitoring of Paracetamol Analgesic in Non-Invasively Collected Saliva for Personalized Medicine. Small. 2023 Mar;19(12):e2206753. doi: 10.1002/smll.202206753. Epub 2023 Jan 15. — View Citation

Ribet F, Bendes A, Fredolini C, Dobielewski M, Bottcher M, Beck O, Schwenk JM, Stemme G, Roxhed N. Microneedle Patch for Painless Intradermal Collection of Interstitial Fluid Enabling Multianalyte Measurement of Small Molecules, SARS-CoV-2 Antibodies, and Protein Profiling. Adv Healthc Mater. 2023 May;12(13):e2202564. doi: 10.1002/adhm.202202564. Epub 2023 Feb 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Methadone Concentration in ISF before and after a dose measure dermal interstitial fluid with LC-MS for methadone before and after a daily dose 1 day
Primary Methadone Concentration in blood before and after a dose measure blood for methadone with LC-MS before and after a daily dose 1 day
Primary Concentration of Methadone in ISF with LC-MS versus Electrochemical Assay measure ISF with two procedures (Liquid Chromatography - Mass Spectroscopy and Differential Pulse Voltammetry. 2 days
Primary Concentration of Methadone in blood with LC-MS versus Electrochemical Assay measure blood with two procedures (Liquid Chromatography - Mass Spectroscopy and Differential Pulse Voltammetry. 2 days
Primary Pearson Correlation of Methadone between ISF and Blood measure blood and ISF methadone with LC-MS and determine pearson correlation 2 days
Primary Pearson Correlation between DPV and LC-MS ISF Methadone measure ISF for methadone by LC-MS and DPV and determine Pearson correlation 2 days
Primary Pearson Correlation between DPV and LC-MS ISF EDDP measure ISF for EDDP by LC-MS and DPV and determine Pearson correlation 2 days
Primary Pearson Correlation between DPV and LC-MS blood EDDP measure blood for EDDP by LC-MS and DPV and determine Pearson correlation 2 days
Primary EDDP concentration in ISF before and after daily dose of methadone measure ISF for EDDP by LC-MS before and after daily dose of methadone 1 day
Primary EDDP concentration in blood before and after daily dose of methadone measure blood for EDDP by LC-MS before and after daily dose of methadone 1 day
Primary EMDP concentration in ISF before and after daily dose of methadone measure EMDP in ISF before and after daily dose of methadone 1 day
Primary EMDP concentration in blood before and after daily dose of methadone measure EMDP in blood by LC-MS before and after daily dose of methadone 1 day
Primary Pearson Correlation of Methadone to Metabolite Ratio ( MMR ) between ISF and Blood using LC-MS Calculate methadone to EDDP ratio of ISF and Blood and determine Pearson Correlation using LC-MS 2 days
Primary Pearson Correlation of Methadone to Metabolite Ratio ( MMR ) between ISF and Blood using DPV Calculate methadone to EDDP ratio of ISF and Blood and determine Pearson Correlation using DPV 2 days
See also
  Status Clinical Trial Phase
Completed NCT05452499 - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae N/A
Recruiting NCT05037682 - Pain and Opioid Management in Older Adults N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05382962 - iCanCope With Post-Operative Pain (iCanCope PostOp) N/A
Recruiting NCT04285112 - SPRINT: Signature for Pain Recovery IN Teens
Active, not recruiting NCT04850079 - EHR Precision Drug Treatment in Neonates
Completed NCT03271151 - Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty Phase 4
Completed NCT03272139 - Interscalene Block Versus Superior Trunk Block Phase 4
Completed NCT03886142 - Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis N/A
Recruiting NCT05761392 - APP-based Precise Management System of Chronic Intractable Pain N/A
Recruiting NCT05877157 - Pain AND Opioids After Surgery
Completed NCT03947749 - Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
Completed NCT03280017 - Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain Phase 4
Recruiting NCT04874038 - Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) Phase 3
Completed NCT04280796 - Changes in Affective Pain Processing in Human Volunteers N/A
Withdrawn NCT05125978 - Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain Phase 2
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Completed NCT04976738 - A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain Phase 1/Phase 2
Completed NCT04089618 - Meditation Based Lifestyle Modification in Chronic Pain N/A
Recruiting NCT05699837 - Alpha Entrainment for Pain and Sleep (Extension) N/A

External Links